Author:
Harbeson Scott L.,Morgan Adam J.,Liu Julie F.,Aslanian Ara M.,Nguyen Sophia,Bridson Gary W.,Brummel Christopher L.,Wu Lijun,Tung Roger D.,Pilja Lana,Braman Virginia,Uttamsingh Vinita
Publisher
American Society for Pharmacology & Experimental Therapeutics (ASPET)
Subject
Pharmacology,Molecular Medicine
Reference31 articles.
1. Ivacaftor in cystic fibrosis: the first disease modifying agent;Aditya;Int J Basic Clin Pharmacol,2012
2. Metabolic switching in cyctochrome P-450cam: deuterium isotope effects on regiospecificity and the monooxygenase/oxidase ratio
3. Austedo. (2017) Package insert. Teva Pharmaceuticals USA, North Wales, PA.
4. The use of stable isotopes in pharmacological research;Baillie;Pharmacol Rev,1981
5. Fink A, Sawicki GS, Morgan WJ, Schechter MS, Rosenfeld M, and Marshall BC (2015) Treatment response to ivacaftor in clinical practice: analysis of the US CF Foundation patient registry. Pediatr Pulmonol 50:361 (Abstract 450).
Cited by
59 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献